BERINGIA LIU: Open Payments
NPI 1801565494 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$607 in 24 payments from 10 companies in 2025. Trend: 2023 $816 · 2024 $748 · 2025 $607
Food & beverage: $607
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $256 |
| Amgen Inc. | 5 | $94 |
| Lilly USA, LLC | 3 | $71 |
| PFIZER INC. | 2 | $56 |
| ABBVIE INC. | 1 | $31 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Exact Sciences Corporation | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $16 |
Products named: Ozempic, REPATHA, Wegovy, NURTEC ODT, MOUNJARO, CREON, SHINGRIX, ZEPBOUND.
Industry payments across CA — which companies pay providers there.
